Wave Life Sciences, Inc. (WVE): Total Liabilities
$112.27M
As of 2025-12-31
$104.80M
As of 2026-06-30
-15.1%
3-year compound annual growth
-9.9%
5-year compound annual growth
+39.4%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $112.27M | -16.7% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $134.82M | -40.7% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $227.44M | +23.9% | 2025-03-04, Balance as of period end |
| 2022-12-31 | $183.60M | +10.2% | 2024-03-06, Balance as of period end |
| 2021-12-31 | $166.63M | -11.6% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $188.59M | -11.3% | 2022-03-03, Balance as of period end |
| 2019-12-31 | $212.64M | -1.0% | 2021-03-04, Balance as of period end |
| 2018-12-31 | $214.72M | +524.9% | 2020-03-02, Balance as of period end |
| 2017-12-31 | $34.36M | +55.7% | 2019-03-01, Balance as of period end |
| 2016-12-31 | $22.07M | +443.8% | 2018-03-12, Balance as of period end |
| 2015-12-31 | $4.06M | +345.6% | 2017-03-16, Balance as of period end |
| 2014-12-31 | $911.0K | n/a | 2016-03-30, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | $112.27M | -16.7% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $119.41M | +123.3% |
| Biofrontera Inc. (BFRI) | 2025-12-31 | $18.08M | +2.4% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $52.28M | -1.4% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $194.09M | +20.1% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $214.26M | +486.9% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $53.48M | -23.0% |
| BGM Group Ltd. (BGM) | 2025-09-30 | $41.92M | +370.4% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $295.01M | +3.2% |
Compare WVE, XLO, BFRI, CPIX side by side · Screen every company in Pharmaceutical Preparations ↗